Clinical Trial Update: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update covers a Phase 1/2 clinical trial of 9MW2821 in combination with toripalimab for advanced urothelial carcinoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• 9MW2821
• Toripalimab (Toripalimab)

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: RECRUITING